How Do You Run a Distributor Relabelling Workflow Under MDR Article 16

36 minutes ago

6 min read

Auditors reviewing ISO quality management evidence for a medical device relabelling file

Relabel a device that's already on the EU market, or just translate its instructions for use, and you can't sell it for another 28 days. That's the notice period Article 16 of the Medical Device Regulation (Regulation (EU) 2017/745) sets: 28 days to inform the manufacturer and the competent authority, and to hand over a specimen on request, before the relabelled device reaches a single shelf.

AD VERBUM is an EU-hosted translation company that runs distributor and importer relabelling under a certified Article 16(3) quality management system, pairing client-tuned LLM output with certified medical linguists and ISO 13485, ISO 17100 and ISO 27001 processes. We handle the translation, the specimen, and the terminology control the whole workflow turns on.

Get one step out of order and the device sits in a warehouse, or a competent authority decides you're the manufacturer. Here's the sequence that keeps a relabelling operation inside Article 16(2), together with the post-market language obligations that decide whether the translated label passes.

What Article 16 actually covers

Article 16 draws a hard line. Under Article 16(1), an importer or distributor who makes a device available under their own name, changes its intended purpose, or modifies it in a way that could affect compliance takes on the full manufacturer obligations of Article 10, including the CE conformity route. That is not what most relabelling is.

Article 16(2) carves out two activities that don't make you the manufacturer: providing the information the manufacturer supplied, translation included, for a device already on the market; and changing the outer packaging, including pack size, where that repackaging is necessary to market the device in a given member state. Translate a paper or electronic IFU into Finnish for the Finnish market, and you stay a distributor, provided you meet the conditions in Article 16(3).

The "necessary to market" test matters. You have to justify why the change was needed for that member state, not merely convenient. The national-language obligation behind the translation comes from MDR Article 10(11) and Annex I, Section 23.1(d), which require the label and IFU in the official language(s) each member state accepts.

Scope has edges. The Article 16(4) certification scheme covers the device categories coded in Implementing Regulation (EU) 2017/2185. Devices supplied in a sterile condition and legacy devices sit outside it, so check the code before you build the workflow.

Distributor staff handling a device and its translated packaging in a compliance workspace

The relabelling workflow, step by step

Run it in this order. Each step gates the next, and the 28-day clock only starts once the earlier steps are done.

Confirm the work sits under Article 16(2). If you're adding a claim, changing the intended purpose, or altering anything that touches conformity, you're under Article 16(1) and the manufacturer obligations apply. Translation of the manufacturer's own information and a pack-size change do not cross that line.
Build a quality management system to Article 16(3). It needs documented procedures that keep translations accurate and up to date, keep the device in its original condition through repackaging, keep the new packaging sound, and keep you informed of any manufacturer corrective action. The requirements track EN ISO 13485, though no single standard is mandated, and the whole record should sit on secure, auditable infrastructure.
Get an Article 16(4) certificate from a notified body designated for those devices. The body audits your QMS against Article 16(3) across initial, surveillance and recertification audits, at your sites and any subcontractor doing the relabelling. Confirm the body runs Article 16(4) reviews in the NANDO database before you apply, and read the certification detail in MDCG 2021-23.
Translate the label and IFU, and keep them current. This is where the certified linguistics live: the wording has to match the manufacturer's approved terminology, and any change the manufacturer issues has to flow into every language version, not just the market that prompted it.
Mark the packaging. Indicate the relabelling or repackaging activity together with your name, registered trade name and registered address, using the ISO 15223-1 symbols that identify the party responsible for translation or repackaging.
Notify, then wait 28 days. At least 28 calendar days before the relabelled device is made available, inform the manufacturer and the competent authority of each member state where you'll sell it, and provide a specimen or mock-up, including the translated label and IFU, on request.
Keep the corrective-action link live. Your QMS has to carry every manufacturer safety action into your relabelled stock for as long as that stock is on the market.

Only after the notified body has certified the QMS and the notice period has run does the relabelled device go on sale.

Linguist annotating a translated instructions-for-use proof before notification

Where it goes wrong

The failures cluster in a few places. Watch these:

Treating an NDA as a QMS. A confidentiality agreement with a freelancer doesn't satisfy Article 16(3). You need documented, audited procedures a notified body can certify.
Missing a language when the manufacturer updates. A corrective action or a revised field safety notice that reaches five markets but not the sixth breaks the "accurate and up to date" condition and leaves stale copy on shelf.
Adding a claim in translation. The moment a translated IFU says something the source didn't, you've modified the device and dropped into Article 16(1) manufacturer territory.
Starting the 28-day clock too early. The notice period runs on a complete package; an incomplete specimen resets it. The Commission's MDCG 2021-26 Q&A sets out what a complete notification looks like.
Assuming a sterile or legacy device qualifies. Both sit outside the Article 16(4) scheme, so the route for those is different and you can't lean on this workflow.

Our medical device translation services

translation services for regulated sectors run on ISO 27001 and ISO 42001 certified, EU-hosted infrastructure, with no reliance on public cloud tooling for core processing. Every project runs through our AI+HUMAN hybrid workflow: we ingest client Translation Memories and Term Bases first, our proprietary LLM-based LangOps System generates output constrained by client terminology on client-tuned open-weight models, and our certified subject-matter experts review for technical accuracy and regulatory compliance. Our QA is aligned to ISO 17100 and ISO 18587, with sector-specific requirements such as ISO 13485 device quality management and MDR Article 16 relabelling controls applied where relevant. We serve Life Sciences, Legal, Finance, Defense, and Manufacturing clients across 150+ languages with 3,500+ subject-matter linguists. For teams managing audit-sensitive content, contact us to discuss your security and compliance requirements directly.

FAQ

Does translating an IFU make me the manufacturer under MDR?

No, provided you stay inside Article 16(2). Translating the information the manufacturer supplied, for a device already on the market, is not a modification that shifts manufacturer obligations to you, as long as you meet the Article 16(3) conditions and hold an Article 16(4) certificate.

What is an Article 16(4) certificate?

It's a certificate issued by a notified body confirming that your quality management system meets Article 16(3) for translation, relabelling or repackaging. The notified body has to be designated for the device type, and it audits you on an initial, surveillance and recertification basis.

How much notice do I have to give before selling a relabelled device?

At least 28 calendar days. Before the relabelled or repackaged device is made available, you inform the manufacturer and the competent authority of each member state concerned, and provide a specimen or mock-up, including the translated label and IFU, on request under Article 16(2).

Which languages does the translated label and IFU need?

The official language(s) that each member state where the device is sold accepts, under MDR Article 10(11) and Annex I, Section 23.1(d). The translation has to stay accurate and up to date, so a manufacturer revision has to reach every language version you maintain.

Do sterile devices and legacy devices fall under the Article 16(4) scheme?

No. Devices supplied in a sterile condition and legacy devices are outside the Article 16(4) certification scheme. The relabelling route for those is different, so confirm the device's status against Implementing Regulation (EU) 2017/2185 before you start.

What does a compliant Article 16(3) quality management system need?

Documented procedures that keep translations accurate and up to date, preserve the device's original condition through repackaging, keep the new packaging sound, and pull every manufacturer corrective action into your relabelled stock. The requirements track EN ISO 13485, though no single standard is mandated.